Therapies for Treatment-Resistant Panic Disorder Symptoms

Status Completed

Clinical Trial Summary

This study will determine the effectiveness of different treatments for panic disorder symptoms in individuals who still have symptoms after initial treatment with medication.

Clinical Trial Description

Panic disorder is a serious condition that may cause significant psychological and physical distress. Many patients with panic disorder remain symptomatic despite initial intervention. Unfortunately, little data is available to guide health care providers in "next-step" treatment approaches. This study will evaluate the effectiveness of treatments for individuals with panic disorder that is resistant to initial treatment with selective serotonin reuptake inhibitors (SSRIs).

This study will last 24 weeks and will comprise three phases. In Phase 1, participants will receive the SSRI sertraline for 6 weeks. Phase 1 will be used to determine participants' resistance to treatment. During Phase 1, participants will begin a medication schedule and symptom diary and will have weekly study visits to assess regimen adherence and any side effects they may be experiencing. In Phase 2, participants will be randomly assigned to 6 weeks of one of two treatments: sertraline at an elevated dose from that given in Phase 1 or a sertraline and placebo regimen. During Phase 2, participants will have 3 study visits. Self-report scales and diary entries will be used to assess panic disorder symptoms and medication side effects. In Phase 3, participants will be randomly assigned to receive either cognitive behavioral therapy (CBT) or sertraline and clonazepam for 12 weeks. All participants will have weekly study visits during Phase 3. Questionnaires and self-report scales will be used to assess participants at the end of Phase 3.

Study hypothesis: Combined selective serotonin reuptake inhibitors (SSRIs) and benzodiazepine treatment, increasing the dose of SSRI, and the addition of cognitive behavioral therapy (CBT) each may have benefits for patients with panic disorder who remain symptomatic after initial treatment with SSRIs. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Panic Disorder

Clinical Trial Details

NCT number	NCT00118417
Study type	Interventional
Source	Massachusetts General Hospital
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	March 1999
Completion date	October 2007

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05868135` - Effects and Cost-effectiveness of e-Meistring - a Guided Internet-delivered Psychological Treatment
Active, not recruiting	`NCT05530642` - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel	N/A
Completed	`NCT02998502` - The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens	N/A
Completed	`NCT01955954` - Using the Canary Breathing System for Panic Disorder Patients	N/A
Completed	`NCT01963806` - ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder	N/A
Completed	`NCT01201967` - A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients	Phase 4
Completed	`NCT00711737` - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months	N/A
Completed	`NCT00525226` - Evaluating the Effects of Stress in Pregnancy	N/A
Completed	`NCT00605813` - Special Investigation Of Long Term Use Of Sertraline.
Completed	`NCT00353470` - Comparison of Psychotherapy Programs to Treat Panic Disorder	Phase 3
Completed	`NCT00167479` - A Study of Risperidone Monotherapy in Bipolar Anxiety	Phase 4
Completed	`NCT00540098` - Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder	Phase 4
Completed	`NCT03233542` - The Association Between Physical Sensations and Thinking Styles	N/A
Recruiting	`NCT05967468` - Evaluation of Family-Based Behavioral Treatments for Youth With Anxiety and Obsessive-Compulsive Disorder	N/A
Completed	`NCT02811458` - Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders	N/A
Active, not recruiting	`NCT05124639` - Clinical Trial of a Group Self-management Support Program for Anxiety Disorders	N/A
Completed	`NCT04592536` - A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects	Phase 1
Completed	`NCT00025974` - Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder	N/A
Recruiting	`NCT02305537` - Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment	N/A
Terminated	`NCT01680107` - D-cycloserine Augmented CBT for Panic Disorder	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.